| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 54 | 2022 | 3837 | 4.430 |
Why?
|
| Analgesics | 33 | 2021 | 1072 | 3.420 |
Why?
|
| Pain Measurement | 53 | 2024 | 3585 | 3.400 |
Why?
|
| Pain | 43 | 2021 | 5100 | 3.120 |
Why?
|
| Opioid-Related Disorders | 29 | 2020 | 2189 | 2.790 |
Why?
|
| Low Back Pain | 17 | 2024 | 990 | 2.340 |
Why?
|
| Sensory System Agents | 4 | 2016 | 24 | 1.950 |
Why?
|
| Capsaicin | 4 | 2016 | 235 | 1.790 |
Why?
|
| Oxycodone | 7 | 2022 | 144 | 1.520 |
Why?
|
| Osteoarthritis, Knee | 10 | 2019 | 1255 | 1.510 |
Why?
|
| Naproxen | 3 | 2019 | 101 | 1.280 |
Why?
|
| Neuralgia, Postherpetic | 4 | 2015 | 41 | 1.150 |
Why?
|
| Transdermal Patch | 4 | 2016 | 51 | 1.140 |
Why?
|
| Diabetic Neuropathies | 4 | 2021 | 410 | 1.120 |
Why?
|
| Neuralgia | 8 | 2021 | 622 | 1.100 |
Why?
|
| Clinical Trials as Topic | 26 | 2019 | 8055 | 1.070 |
Why?
|
| Morphinans | 4 | 2020 | 27 | 1.040 |
Why?
|
| Chemistry, Pharmaceutical | 5 | 2011 | 275 | 1.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 10 | 2019 | 2277 | 1.000 |
Why?
|
| Double-Blind Method | 37 | 2024 | 12469 | 0.990 |
Why?
|
| Prescription Drugs | 6 | 2013 | 635 | 0.970 |
Why?
|
| Placebo Effect | 4 | 2021 | 518 | 0.950 |
Why?
|
| Naltrexone | 3 | 2011 | 319 | 0.890 |
Why?
|
| Morphine | 5 | 2016 | 658 | 0.860 |
Why?
|
| Drug and Narcotic Control | 5 | 2011 | 145 | 0.830 |
Why?
|
| Substance-Related Disorders | 9 | 2016 | 4429 | 0.780 |
Why?
|
| Cyclooxygenase Inhibitors | 4 | 2004 | 361 | 0.760 |
Why?
|
| Drug Prescriptions | 7 | 2011 | 1673 | 0.740 |
Why?
|
| Cross-Over Studies | 12 | 2021 | 2108 | 0.720 |
Why?
|
| Hyperalgesia | 2 | 2015 | 527 | 0.710 |
Why?
|
| Hydrocodone | 4 | 2022 | 48 | 0.700 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2021 | 10397 | 0.660 |
Why?
|
| Uterine Diseases | 1 | 2020 | 108 | 0.660 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2018 | 465 | 0.650 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2018 | 117 | 0.630 |
Why?
|
| Behavior, Addictive | 2 | 2015 | 433 | 0.590 |
Why?
|
| Equipment Safety | 1 | 2018 | 250 | 0.550 |
Why?
|
| Delayed-Action Preparations | 8 | 2022 | 969 | 0.550 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 878 | 0.550 |
Why?
|
| Risk Management | 5 | 2016 | 558 | 0.540 |
Why?
|
| Arthralgia | 3 | 2018 | 459 | 0.510 |
Why?
|
| Health Care Costs | 3 | 2020 | 3270 | 0.510 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2015 | 34 | 0.510 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 4 | 2014 | 321 | 0.500 |
Why?
|
| Equipment and Supplies | 1 | 2018 | 274 | 0.490 |
Why?
|
| Education | 1 | 2018 | 533 | 0.490 |
Why?
|
| Research Design | 16 | 2021 | 6213 | 0.490 |
Why?
|
| Osteoarthritis, Hip | 3 | 2017 | 409 | 0.440 |
Why?
|
| Humans | 150 | 2024 | 768887 | 0.440 |
Why?
|
| Substance Abuse Detection | 5 | 2013 | 301 | 0.430 |
Why?
|
| Lactones | 3 | 2004 | 316 | 0.420 |
Why?
|
| Phenols | 3 | 2015 | 523 | 0.420 |
Why?
|
| Documentation | 2 | 2018 | 917 | 0.420 |
Why?
|
| Narcotics | 4 | 2016 | 334 | 0.410 |
Why?
|
| Treatment Outcome | 44 | 2024 | 65485 | 0.410 |
Why?
|
| Health Surveys | 6 | 2016 | 4055 | 0.410 |
Why?
|
| Drug Monitoring | 3 | 2010 | 965 | 0.400 |
Why?
|
| Endometriosis | 1 | 2020 | 874 | 0.390 |
Why?
|
| Anesthetics, Local | 4 | 2011 | 1004 | 0.370 |
Why?
|
| Cost of Illness | 4 | 2017 | 1959 | 0.370 |
Why?
|
| Narcotic Antagonists | 3 | 2010 | 591 | 0.370 |
Why?
|
| Heroin | 1 | 2011 | 120 | 0.360 |
Why?
|
| Middle Aged | 57 | 2024 | 223740 | 0.360 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2011 | 371 | 0.340 |
Why?
|
| Actigraphy | 1 | 2014 | 527 | 0.340 |
Why?
|
| Dentists | 1 | 2011 | 176 | 0.330 |
Why?
|
| Adult | 54 | 2024 | 223818 | 0.330 |
Why?
|
| Internet | 4 | 2009 | 3112 | 0.320 |
Why?
|
| Radiculopathy | 2 | 2024 | 203 | 0.320 |
Why?
|
| Pain, Intractable | 2 | 2010 | 132 | 0.320 |
Why?
|
| Male | 66 | 2024 | 365249 | 0.310 |
Why?
|
| Female | 68 | 2024 | 397464 | 0.310 |
Why?
|
| Professional Role | 1 | 2011 | 316 | 0.300 |
Why?
|
| Injections | 2 | 2009 | 841 | 0.300 |
Why?
|
| Endocrine System | 1 | 2009 | 113 | 0.300 |
Why?
|
| Iontophoresis | 1 | 2008 | 75 | 0.300 |
Why?
|
| Aged | 42 | 2024 | 171790 | 0.290 |
Why?
|
| Migraine Disorders | 1 | 2020 | 1713 | 0.290 |
Why?
|
| Managed Care Programs | 1 | 2013 | 941 | 0.290 |
Why?
|
| United States | 24 | 2022 | 73180 | 0.280 |
Why?
|
| Oxymorphone | 1 | 2007 | 6 | 0.280 |
Why?
|
| Databases, Factual | 8 | 2020 | 8095 | 0.280 |
Why?
|
| Self Report | 2 | 2018 | 3773 | 0.280 |
Why?
|
| Chronic Disease | 19 | 2010 | 9384 | 0.280 |
Why?
|
| Osteoarthritis | 3 | 2014 | 1070 | 0.280 |
Why?
|
| Budgets | 1 | 2009 | 232 | 0.280 |
Why?
|
| Ultrasonics | 2 | 2008 | 208 | 0.280 |
Why?
|
| Administrative Personnel | 1 | 2008 | 185 | 0.280 |
Why?
|
| Computer Communication Networks | 1 | 2008 | 295 | 0.270 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2014 | 495 | 0.270 |
Why?
|
| Drug Utilization | 3 | 2011 | 1191 | 0.270 |
Why?
|
| Government Programs | 1 | 2008 | 278 | 0.270 |
Why?
|
| Orthopedic Procedures | 2 | 2015 | 1280 | 0.260 |
Why?
|
| Aged, 80 and over | 22 | 2019 | 59738 | 0.260 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2018 | 716 | 0.260 |
Why?
|
| Knee Joint | 1 | 2014 | 1685 | 0.260 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 318 | 0.260 |
Why?
|
| Ultrasonic Therapy | 1 | 2008 | 217 | 0.260 |
Why?
|
| Drug Administration Schedule | 7 | 2015 | 4862 | 0.260 |
Why?
|
| Anesthesia, Local | 2 | 2008 | 279 | 0.260 |
Why?
|
| Skin | 3 | 2017 | 4507 | 0.250 |
Why?
|
| Paper | 2 | 2002 | 83 | 0.250 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 390 | 0.250 |
Why?
|
| Lidocaine | 2 | 2008 | 546 | 0.240 |
Why?
|
| Analgesia | 2 | 2012 | 460 | 0.230 |
Why?
|
| Prilocaine | 1 | 2004 | 21 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2017 | 10778 | 0.230 |
Why?
|
| Motor Activity | 1 | 2014 | 2722 | 0.220 |
Why?
|
| Population Surveillance | 3 | 2011 | 2597 | 0.220 |
Why?
|
| Cost Savings | 1 | 2009 | 915 | 0.210 |
Why?
|
| Isoxazoles | 2 | 2007 | 233 | 0.210 |
Why?
|
| Adolescent | 22 | 2020 | 89247 | 0.210 |
Why?
|
| Central Nervous System Diseases | 2 | 2017 | 521 | 0.210 |
Why?
|
| Young Adult | 15 | 2020 | 60110 | 0.200 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 5892 | 0.200 |
Why?
|
| Isoenzymes | 2 | 2004 | 1687 | 0.200 |
Why?
|
| Toxicity Tests | 1 | 2002 | 114 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2024 | 1813 | 0.190 |
Why?
|
| Insurance Coverage | 2 | 2020 | 1946 | 0.190 |
Why?
|
| United States Food and Drug Administration | 3 | 2022 | 1672 | 0.190 |
Why?
|
| Nerve Growth Factor | 2 | 2013 | 156 | 0.180 |
Why?
|
| Drug Utilization Review | 2 | 2020 | 248 | 0.180 |
Why?
|
| Acetaminophen | 4 | 2011 | 556 | 0.180 |
Why?
|
| Health Care Surveys | 1 | 2008 | 2437 | 0.180 |
Why?
|
| Microcomputers | 1 | 2001 | 139 | 0.180 |
Why?
|
| Translations | 2 | 2020 | 84 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 8 | 2017 | 7460 | 0.180 |
Why?
|
| Behavior | 1 | 2003 | 543 | 0.180 |
Why?
|
| Computers, Handheld | 1 | 2002 | 211 | 0.180 |
Why?
|
| Nervous System | 1 | 2003 | 547 | 0.170 |
Why?
|
| Insurance Claim Review | 2 | 2020 | 746 | 0.170 |
Why?
|
| Fentanyl | 2 | 2019 | 450 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2020 | 1575 | 0.170 |
Why?
|
| Sample Size | 3 | 2014 | 848 | 0.170 |
Why?
|
| Administration, Intranasal | 2 | 2012 | 485 | 0.170 |
Why?
|
| Program Evaluation | 1 | 2008 | 2507 | 0.170 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2023 | 538 | 0.170 |
Why?
|
| Mucopolysaccharidosis I | 2 | 2017 | 53 | 0.160 |
Why?
|
| Enzyme Replacement Therapy | 2 | 2017 | 80 | 0.160 |
Why?
|
| Demography | 3 | 2009 | 1643 | 0.160 |
Why?
|
| Sulfonamides | 4 | 2010 | 1982 | 0.160 |
Why?
|
| Histamine | 1 | 2021 | 496 | 0.160 |
Why?
|
| Medical Records | 2 | 2002 | 1411 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2011 | 1379 | 0.160 |
Why?
|
| Prevalence | 9 | 2015 | 15875 | 0.150 |
Why?
|
| Natural Language Processing | 1 | 2007 | 1203 | 0.150 |
Why?
|
| Analysis of Variance | 4 | 2015 | 6242 | 0.150 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 15955 | 0.150 |
Why?
|
| History, 20th Century | 2 | 2020 | 2771 | 0.150 |
Why?
|
| Guideline Adherence | 3 | 2013 | 2240 | 0.150 |
Why?
|
| Databases, Bibliographic | 2 | 2016 | 129 | 0.150 |
Why?
|
| Mucopolysaccharidoses | 1 | 2017 | 27 | 0.150 |
Why?
|
| Pelvic Pain | 1 | 2020 | 300 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2009 | 3580 | 0.140 |
Why?
|
| Triamcinolone Acetonide | 1 | 2018 | 105 | 0.140 |
Why?
|
| Reproducibility of Results | 10 | 2015 | 20244 | 0.140 |
Why?
|
| Sulfones | 3 | 2004 | 448 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 640 | 0.140 |
Why?
|
| Polyamines | 1 | 2017 | 133 | 0.140 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 2862 | 0.140 |
Why?
|
| Drug Information Services | 1 | 2016 | 51 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2024 | 1965 | 0.130 |
Why?
|
| Medical Informatics Applications | 1 | 2018 | 180 | 0.130 |
Why?
|
| Iduronidase | 1 | 2016 | 31 | 0.130 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2021 | 1143 | 0.130 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2017 | 420 | 0.130 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2016 | 81 | 0.130 |
Why?
|
| Oral Surgical Procedures | 2 | 2011 | 172 | 0.130 |
Why?
|
| Sensory Thresholds | 1 | 2017 | 377 | 0.130 |
Why?
|
| Models, Psychological | 2 | 2009 | 826 | 0.120 |
Why?
|
| Data Collection | 3 | 2012 | 3322 | 0.120 |
Why?
|
| Time Factors | 9 | 2017 | 40266 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 3 | 2011 | 2714 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 2194 | 0.120 |
Why?
|
| Pain, Postoperative | 2 | 2018 | 1765 | 0.120 |
Why?
|
| Disability Evaluation | 5 | 2016 | 1839 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2019 | 811 | 0.120 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2017 | 648 | 0.120 |
Why?
|
| Medication Errors | 2 | 2018 | 784 | 0.110 |
Why?
|
| Inappropriate Prescribing | 1 | 2016 | 212 | 0.110 |
Why?
|
| Rest | 1 | 2019 | 951 | 0.110 |
Why?
|
| Health Planning Guidelines | 2 | 2005 | 153 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 1088 | 0.110 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 417 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2017 | 797 | 0.110 |
Why?
|
| Drug Tolerance | 1 | 2015 | 366 | 0.110 |
Why?
|
| Pain Perception | 1 | 2014 | 198 | 0.110 |
Why?
|
| Publication Bias | 1 | 2013 | 159 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2023 | 1459 | 0.100 |
Why?
|
| Dependovirus | 1 | 2018 | 721 | 0.100 |
Why?
|
| Drug Combinations | 2 | 2009 | 2088 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 15471 | 0.100 |
Why?
|
| Drug Compounding | 2 | 2017 | 243 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 39394 | 0.100 |
Why?
|
| Independent Living | 1 | 2016 | 584 | 0.100 |
Why?
|
| Publications | 1 | 2014 | 195 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2011 | 4042 | 0.100 |
Why?
|
| Quality of Life | 4 | 2016 | 13510 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2017 | 864 | 0.100 |
Why?
|
| Genetic Engineering | 1 | 2018 | 936 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2016 | 5323 | 0.100 |
Why?
|
| Dental Staff | 1 | 2011 | 14 | 0.100 |
Why?
|
| Hydromorphone | 1 | 2012 | 70 | 0.100 |
Why?
|
| Movement | 1 | 2019 | 1490 | 0.100 |
Why?
|
| Dentist-Patient Relations | 1 | 2011 | 30 | 0.100 |
Why?
|
| General Practice, Dental | 1 | 2011 | 32 | 0.090 |
Why?
|
| ROC Curve | 1 | 2019 | 3629 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 2018 | 3414 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2015 | 2359 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 599 | 0.090 |
Why?
|
| Fraud | 1 | 2011 | 66 | 0.090 |
Why?
|
| Pain Threshold | 1 | 2014 | 606 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2001 | 2701 | 0.090 |
Why?
|
| Cost Control | 1 | 2013 | 627 | 0.090 |
Why?
|
| Risk Assessment | 6 | 2021 | 24330 | 0.090 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2015 | 628 | 0.090 |
Why?
|
| Drug Approval | 1 | 2017 | 820 | 0.090 |
Why?
|
| Complementary Therapies | 1 | 2014 | 487 | 0.090 |
Why?
|
| Pentazocine | 1 | 2009 | 12 | 0.090 |
Why?
|
| Long-Term Care | 2 | 2005 | 632 | 0.090 |
Why?
|
| Endpoint Determination | 2 | 2013 | 594 | 0.080 |
Why?
|
| Capsules | 1 | 2010 | 193 | 0.080 |
Why?
|
| Morphine Dependence | 1 | 2009 | 27 | 0.080 |
Why?
|
| Lumbosacral Region | 2 | 2024 | 294 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2014 | 8742 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2017 | 2357 | 0.080 |
Why?
|
| Surgery, Oral | 1 | 2011 | 133 | 0.080 |
Why?
|
| Genotype | 2 | 2021 | 13048 | 0.080 |
Why?
|
| Placebos | 2 | 2010 | 1668 | 0.080 |
Why?
|
| Electronic Prescribing | 1 | 2010 | 115 | 0.080 |
Why?
|
| Euphoria | 1 | 2008 | 65 | 0.080 |
Why?
|
| Buprenorphine | 1 | 2016 | 667 | 0.080 |
Why?
|
| Palliative Care | 1 | 2003 | 3644 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 1398 | 0.080 |
Why?
|
| Terminology as Topic | 3 | 2013 | 1541 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 9264 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2010 | 475 | 0.070 |
Why?
|
| Massachusetts | 2 | 2012 | 8888 | 0.070 |
Why?
|
| Phenotype | 3 | 2021 | 16735 | 0.070 |
Why?
|
| Neoplasms | 1 | 2016 | 22390 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 10591 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2008 | 1585 | 0.070 |
Why?
|
| Naloxone | 1 | 2009 | 372 | 0.070 |
Why?
|
| History, Ancient | 1 | 2007 | 213 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2011 | 1421 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2009 | 1169 | 0.070 |
Why?
|
| Blood Donors | 1 | 2008 | 344 | 0.070 |
Why?
|
| Alcoholism | 1 | 2017 | 1981 | 0.070 |
Why?
|
| Internationality | 2 | 2012 | 1008 | 0.070 |
Why?
|
| Bacteria | 1 | 2017 | 2219 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 725 | 0.060 |
Why?
|
| Attitude of Health Personnel | 2 | 2011 | 3925 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 2517 | 0.060 |
Why?
|
| Child | 7 | 2017 | 80969 | 0.060 |
Why?
|
| Legislation, Drug | 1 | 2007 | 216 | 0.060 |
Why?
|
| Health Priorities | 1 | 2008 | 380 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4568 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 6031 | 0.060 |
Why?
|
| Butanones | 1 | 2004 | 23 | 0.060 |
Why?
|
| Sufentanil | 1 | 2004 | 42 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 4415 | 0.060 |
Why?
|
| Age of Onset | 1 | 2012 | 3346 | 0.060 |
Why?
|
| Neurology | 1 | 2012 | 787 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2023 | 81892 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2012 | 1068 | 0.060 |
Why?
|
| Epinephrine | 1 | 2008 | 794 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2008 | 657 | 0.060 |
Why?
|
| Animals | 9 | 2020 | 169408 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 4794 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 2005 | 411 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4879 | 0.050 |
Why?
|
| Gels | 1 | 2024 | 422 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2565 | 0.050 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2003 | 113 | 0.050 |
Why?
|
| Herpes Zoster | 1 | 2004 | 252 | 0.050 |
Why?
|
| Dogs | 2 | 2017 | 3845 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2016 | 6434 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 41800 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2007 | 971 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5953 | 0.050 |
Why?
|
| Psychophysics | 1 | 2002 | 291 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2004 | 281 | 0.050 |
Why?
|
| Counseling | 1 | 2009 | 1554 | 0.050 |
Why?
|
| Pyrazoles | 3 | 2010 | 2029 | 0.050 |
Why?
|
| Drug Costs | 1 | 2009 | 1198 | 0.050 |
Why?
|
| Dysmenorrhea | 1 | 2002 | 107 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2002 | 248 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 2339 | 0.050 |
Why?
|
| Urine | 1 | 2002 | 362 | 0.040 |
Why?
|
| Logistic Models | 1 | 2015 | 13317 | 0.040 |
Why?
|
| Anxiety | 1 | 2015 | 4677 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2002 | 1629 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2005 | 1445 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2023 | 917 | 0.040 |
Why?
|
| Incidence | 1 | 2018 | 21545 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2012 | 10115 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 7860 | 0.040 |
Why?
|
| Receptors, Opioid | 1 | 2019 | 145 | 0.040 |
Why?
|
| Partnership Practice | 1 | 2018 | 14 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2014 | 3463 | 0.040 |
Why?
|
| Risk Factors | 6 | 2023 | 74971 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3709 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2003 | 1209 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2019 | 54950 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 26384 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2238 | 0.040 |
Why?
|
| Patient Selection | 3 | 2019 | 4265 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2011 | 3626 | 0.040 |
Why?
|
| Spermine | 1 | 2017 | 70 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2005 | 2742 | 0.040 |
Why?
|
| Angiography | 1 | 2023 | 1598 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2009 | 9682 | 0.040 |
Why?
|
| Administration, Buccal | 1 | 2016 | 14 | 0.040 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2017 | 75 | 0.030 |
Why?
|
| Registries | 1 | 2013 | 8384 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2002 | 749 | 0.030 |
Why?
|
| Injections, Intra-Articular | 1 | 2018 | 288 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 408 | 0.030 |
Why?
|
| Ontario | 1 | 2017 | 403 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2004 | 7885 | 0.030 |
Why?
|
| Algorithms | 2 | 2009 | 14199 | 0.030 |
Why?
|
| TRPV Cation Channels | 1 | 2017 | 244 | 0.030 |
Why?
|
| Depression | 1 | 2015 | 8240 | 0.030 |
Why?
|
| Mass Screening | 1 | 2011 | 5455 | 0.030 |
Why?
|
| Psychometrics | 2 | 2015 | 3066 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2017 | 250 | 0.030 |
Why?
|
| Public Health | 1 | 2008 | 2680 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2018 | 902 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2011 | 4748 | 0.030 |
Why?
|
| Microspheres | 1 | 2018 | 789 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2018 | 468 | 0.030 |
Why?
|
| Health Personnel | 1 | 2008 | 3382 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2018 | 2299 | 0.030 |
Why?
|
| Population | 1 | 2013 | 141 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2014 | 139 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2004 | 2660 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2016 | 611 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 1970 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 2749 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2017 | 582 | 0.030 |
Why?
|
| Motivation | 1 | 2022 | 2030 | 0.030 |
Why?
|
| Smoking | 1 | 2009 | 9094 | 0.030 |
Why?
|
| Transgenes | 1 | 2016 | 1016 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2018 | 1209 | 0.030 |
Why?
|
| Amines | 1 | 2014 | 280 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 1002 | 0.020 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 123 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 1150 | 0.020 |
Why?
|
| Louisiana | 1 | 2011 | 104 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 22294 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 7148 | 0.020 |
Why?
|
| Uncertainty | 1 | 2015 | 769 | 0.020 |
Why?
|
| Swine | 1 | 2020 | 5998 | 0.020 |
Why?
|
| Tramadol | 1 | 2010 | 63 | 0.020 |
Why?
|
| Facial Pain | 1 | 2011 | 120 | 0.020 |
Why?
|
| Health Status | 1 | 2003 | 4095 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 27476 | 0.020 |
Why?
|
| Leg | 1 | 2015 | 1089 | 0.020 |
Why?
|
| Consensus | 1 | 2019 | 3214 | 0.020 |
Why?
|
| Probability Theory | 1 | 2008 | 11 | 0.020 |
Why?
|
| Computational Biology | 1 | 2021 | 3562 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2017 | 2126 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 367 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2008 | 138 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 18366 | 0.020 |
Why?
|
| HIV Infections | 1 | 2014 | 17589 | 0.020 |
Why?
|
| Publishing | 1 | 2014 | 837 | 0.020 |
Why?
|
| Body Weight | 1 | 2017 | 4628 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3441 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 2396 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 13427 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 6346 | 0.020 |
Why?
|
| Gene Expression | 1 | 2018 | 7602 | 0.020 |
Why?
|
| Weights and Measures | 1 | 2005 | 41 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 14751 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 2013 | 1409 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2004 | 158 | 0.010 |
Why?
|
| Mutism | 1 | 2003 | 27 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2004 | 642 | 0.010 |
Why?
|
| Vertebral Artery | 1 | 2003 | 185 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2015 | 6413 | 0.010 |
Why?
|
| Hospitals | 1 | 2015 | 3903 | 0.010 |
Why?
|
| Quadriplegia | 1 | 2003 | 227 | 0.010 |
Why?
|
| Risk | 1 | 2013 | 9621 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 1470 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 12798 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 16051 | 0.010 |
Why?
|
| Focus Groups | 1 | 2007 | 1461 | 0.010 |
Why?
|
| International Cooperation | 1 | 2007 | 1436 | 0.010 |
Why?
|
| Mice | 2 | 2018 | 82074 | 0.010 |
Why?
|
| Acute Disease | 1 | 2011 | 7245 | 0.010 |
Why?
|
| Eye Movements | 1 | 2003 | 514 | 0.010 |
Why?
|
| Sleep | 1 | 2015 | 4820 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 22381 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2017 | 42684 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 3274 | 0.010 |
Why?
|
| Age Factors | 1 | 2013 | 18454 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 2433 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13699 | 0.010 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2004 | 1177 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 12093 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 30266 | 0.010 |
Why?
|
| Emotions | 1 | 2003 | 2768 | 0.010 |
Why?
|
| Communication | 1 | 2003 | 3908 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 13020 | 0.000 |
Why?
|
| Infant | 1 | 2003 | 36541 | 0.000 |
Why?
|